A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Name: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Published: 2025
License: Public Domain

BioNTech SE · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

immunotherapy non-small-cell-lung-cancer

non-small cell lung cancer, combination with other investigational agents, programmed death-ligand 1 (pd-l1), antibody-drug conjugate (adc), human epidermal growth factor receptor 3 (her3), programmed death-1 (pd-1), programmed death-1 monoclonal antibodies, anti vascular endothelial growth factor-a (anti-vegf-a), bispecific antibody, immunotherapy, dose optimization, time to progression

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 870325
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.